SecBot SecBot
SECBOTREPLAY Home › Report › IVVD

IVVD · Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating…

Invivyd · PRESS-RELEASE filed May 14, 2026 at 07:01 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed May 14, 2026 at 07:01 ET

Invivyd reported Q1 2026 PEMGARDA revenue of $13.7M (+22% YoY), beating consensus estimates on both revenue ($13.7M vs $18.1M expected) and EPS (-$0.04 vs -$0.08 expected). The company highlighted continued in vitro neutralizing activity against the BA.3.2.2 variant, IDMC recommendation to reduce post-dose monitoring time for VYD2311, and a strong cash position of $184.2M providing runway through the DECLARATION data readout in Q3 2026. However, net loss widened to $41.4M from $16.3M a year ago due to increased R&D spending on the DECLARATION trial, and the company raised ~$20M via ATM in April.

  • Q1 2026 PEMGARDA net product revenue $13.7M, up 22% from $11.3M in Q1 2025
  • EPS -$0.04 beat consensus of -$0.08 (50% beat)
  • Revenue $13.7M missed consensus of $18.1M (24% miss)
  • Net loss widened to $41.4M from $16.3M YoY, driven by $30.7M R&D (vs $10.6M)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access